The role of blinatumomab in ALL
Novel agents in CLL: the importance of affordability
Changes in research to overcome the problem of resistance to new CLL drugs
Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?
Changing epigenetic markers in CLL patients on ibrutinib